Inter-rater and intra-rater agreement on the Nordic Orofacial Test—Screening examination in children, adolescents and young adults with cerebral palsy
DOI:
https://doi.org/10.3109/00016357.2013.810771Keywords:
facial paralysis, speech disorders, observer variation, reproducibility of resultsAbstract
Objective. To evaluate inter-rater and intra-rater agreement on the Nordic Orofacial Test–Screening (NOT-S) examination applied to children, adolescents and young adults with cerebral palsy (CP). Materials and methods. Using the NOT-S examination, two speech and language pathologists independently assessed video recordings of 48 subjects with CP aged 5–22 years and representing all CP sub-diagnoses and levels of gross motor function and manual ability. Thirty-one subjects were reassessed. Fifteen out of 17 items in the NOT-S examination domains (1) Face at rest, (2) Nose breathing, (3) Facial expression, (4) Masticatory muscle and jaw function, (5) Oral motor function and (6) Speech were rated using a ‘yes’ (dysfunction observed)/‘no’ format, generating an overall score of 0–6. Results. Inter-rater agreement: Twelve out of 15 items and five out of six domains showed acceptable unweighted kappa values (κ = 0.46–1.00). The lowest kappa value was found for domain 4 (κ = −0.04), although it had high inter-rater agreement (92%). The linear weighted kappa value for the overall NOT-S examination score was 0.65 (95% CI = 0.49–0.82). Intra-rater agreement: All items and domains showed acceptable unweighted kappa values (items 0.58–1.00 and 0.59–1.00, domains 0.81–1.00 and 0.62–0.89) for both raters. The linear weighted kappa value for the overall NOT-S examination score was 0.81 (95% CI = 0.63–0.99) for rater A and 0.54 (95% CI = 0.25–0.82) for rater B. Conclusions. The NOT-S examination has acceptable inter-rater and intra-rater agreement when used in young individuals with CP.
Acta Odontologica Scandinavica publishes high quality original research papers as well as critical reviews relevant on diseases of the oral cavity, their treatment, epidemiology and associated biomaterials and their development.